Comparatively, Laboratory Co. of America has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Export data to Excel for your own analysis. 76.2% of Guardant Health shares are held by institutional investors. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). Comparatively, Natera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Guardant Health is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks. Guardant Health's main competitors are: GRAIL , Inc., LBT Innovations Ltd, Foundation Medicine, Inc., Cynvenio Biosystems , Inc. What companies has Guardant Health acquired? Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Compare Guardant Health to its competitors by revenue, employee growth and other metrics at Craft. Learn about Guardant Health , including insurance benefits, retirement benefits, and vacation policy. CareDx has a consensus price target of $58.00, suggesting a potential downside of 13.46%. Comparatively, 1.5% of Quest Diagnostics shares are held by company insiders. GuardantOMNI differs from Guardant360 in that biopharma companies use it for comprehensive genomic profiling in both immuno-oncology and targeted therapy areas. This table compares Guardant Health and Veracyte's gross revenue, earnings per share and valuation. Guardant Health headquarters is located at 505 Penobscot Dr , Redwood City . Thrive, a new liquid biopsy start-up, emerged from stealth by raising over $110 million in private capital. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. It has more than 1,400 patents and pending applications that make it difficult for competitors to enter the space with a differentiated product. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). It posted non-GAAP earnings per share (EPS) of $1.64 beating the consensus estimates by $0.38. Veracyte has a consensus price target of $40.8333, suggesting a potential downside of 24.83%. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. See you at the top! These liquid biopsy tests, which rely on next-generation DNA sequencing to better identify signs of cancer, have become increasingly popular in cancer diagnostics. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Quest Diagnostics has a consensus price target of $126.6471, suggesting a potential upside of 1.97%. 9.9% of Guardant Health shares are held by company insiders. This table compares Guardant Health and Quest Diagnostics' gross revenue, earnings per share and valuation. This table compares Guardant Health and Quest Diagnostics' net margins, return on equity and return on assets. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Comparatively, 8.3% of Veracyte shares are held by company insiders. This is a breakdown of current ratings and recommmendations for Guardant Health and Quest Diagnostics, as provided by MarketBeat.com. Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 – 2025 See what's happening in the market right now with MarketBeat's real-time news feed. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Get short term trading ideas from the MarketBeat Idea Engine. for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 %. Identify stocks that meet your criteria using seven unique stock screeners. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. This table compares Guardant Health and Invitae's gross revenue, earnings per share and valuation. 9.9% of Guardant Health shares are held by company insiders. Comparatively, 78.9% of Quest Diagnostics shares are held by institutional investors. Competitors of Guardant Health include Biodesix, Tempus and 2cureX. Comparatively, Invitae has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Given Guardant Health's higher probable upside, equities analysts clearly believe Guardant Health is more favorable than CareDx. Maxx Chatsko 76.2% of Guardant Health shares are held by institutional investors. Guardant Health, Inc. Common Stock (GH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Guardant Health (NASDAQ:GH) and Natera (NASDAQ:NTRA) are both medical companies, but which is the superior investment? Receive a free world-class investing education from MarketBeat. Guardant Health beats Invitae on 10 of the 14 factors compared between the two stocks. Learn more. Guardant Health Inc is a small-sized business with medium revenue, that is new in its industry. Market data powered by FactSet and Web Financial Group. Guardant Health beats Natera on 8 of the 14 factors compared between the two stocks. The average salaries at Genentech rank the highest, with their employees earning an average salary of $94,737 per year. Click here to find out how this upcoming precious metal explorer is identifying these extremely rare deposits…. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. This is a summary of recent ratings and price targets for Guardant Health and Laboratory Co. of America, as reported by MarketBeat. Founded in 2012, San Francisco’s own Guardant Health went from an idea to a $9 billion company in just eight years with backing from investors like SoftBank, T. Rowe Price, Khosla, and Sequoia.Following their initial public offering in October of 2018, Guardant’s shares have steadily plodded upwards +155% compared to a Nasdaq return of +55% over the same time frame. Webcast Information. Benefits information above is provided anonymously by current and former Guardant Health employees, and may include a summary provided by the employer. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. This table compares Guardant Health and Laboratory Co. of America's net margins, return on equity and return on assets. Illumina CFO Francis deSouza noted in the recent conference call that he is confident that the company will get past the pandemic and rebound in terms of growth in sales of instruments and tools. Both products are in the process of development as a companion diagnostic (CDx) for use in non-small cell lung cancer (NSCLC). Comparatively, 3.1% of CareDx shares are held by company insiders. Learn more. CareDx has lower revenue, but higher earnings than Guardant Health. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Invitae. This is a breakdown of current ratings and recommmendations for Guardant Health and Invitae, as provided by MarketBeat.com. Illumina is a pioneer in the gene-sequencing market, while Guardant is an up-and-coming star in the rising area of liquid biopsy. Learn everything you need to know about successful options trading with this three-part video course. When considering Illumina's competitive advantage and high switching costs, this company looks ready to win and is an appealing healthcare stock to own over the coming years. Get daily stock ideas top-performing Wall Street analysts. Laboratory Co. of America has higher revenue and earnings than Guardant Health. 76.2% of Guardant Health shares are held by institutional investors. This field has transformed science and medicine, and its innovations have made some investors wealthy from its successes. Better Coronavirus Stock: Quidel or Guardant Health? Guardant Health, Inc. was incorporated in 2011 and is … Moreover, Illumina's contributions have played a significant role in this industry by lowering costs and broadening its customer reach. While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. View which stocks are hot on social media with MarketBeat's trending stocks report. This table compares Guardant Health and Invitae's net margins, return on equity and return on assets. Learn about financial terms, types of investments, trading strategies and more. This is a breakdown of current ratings and recommmendations for Guardant Health and Natera, as provided by MarketBeat.com. Fundamental company data provided by Morningstar and Zacks Investment Research. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Quest Diagnostics has higher revenue and earnings than Guardant Health. While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. This table compares Guardant Health and CareDx's net margins, return on equity and return on assets. Natera has a consensus price target of $75.90, suggesting a potential downside of 23.31%. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Guardant Health has higher earnings, but lower revenue than Invitae. Comparatively, 84.1% of Natera shares are held by institutional investors. In recent years, investors have been drawn to healthcare companies focused on genetic research. Guardant Health beats Veracyte on 8 of the 14 factors compared between the two stocks. 9.9% of Guardant Health shares are held by company insiders. Guardant360 has several different applications. Data Sources: Yahoo Finance, Illumina, Guardant Health. Which of these healthcare stocks is a better buy for the long run? Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Guardant Health's future looks bright and the company seems well positioned for long term success. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Germany's Qiagen sees solid growth in … Global Liquid Biopsy Products Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is a well presented and highly researched market synopsis that demonstrates a thoroughly unbiased portrayal of the current market conditions to assist enthusiastic investors and established players to manage high potential growth and steady revenue output through the entire growth span. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks. Do Not Sell My Information. Given Laboratory Co. of America's higher probable upside, analysts plainly believe Laboratory Co. of America is more favorable than Guardant Health. Should you be buying GH stock or one of its competitors? In some cases apparently high growth rates may be caused by data that weren't available in previous years. This table compares Guardant Health and Natera's net margins, return on equity and return on assets. We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. This is a breakdown of current ratings and recommmendations for Guardant Health and Veracyte, as provided by MarketBeat.com. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. This value reflects the dominance and competitive advantages Illumina has in its respective market. CareDx beats Guardant Health on 8 of the 15 factors compared between the two stocks. Companies may grow organically or through acquisition. Jackpot: Drills are Running Hot like Lava for this Company´s South American Super Project, These unique rock formations now host some of the highest-grade gold mineralization on the planet. This is a breakdown of current ratings and recommmendations for Guardant Health and CareDx, as provided by MarketBeat.com. Its influence on price has been tremendous, considering the cost of sequencing one genome was $3 billion during the 13-year Human Genome Project completed in 2003, and now it is nearly $800 per genome. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Looking for new stock ideas? If you've got money invested in the stock market, but are confused as to what to do next...This is the can't miss interview of 2020. • List of GH Customers for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 % . Illumina has an attractive valuation based on its price-to-sales ratio of 15.18, which suggests the stock could run higher in the long term. Returns as of 12/15/2020. This table compares Guardant Health and CareDx's gross revenue, earnings per share and valuation. There are two Lunar programs: Lunar-1 and Lunar-2. The publication provides annual rankings and firm-by-firm editorial, including leading lawyers. All rights reserved. Advanced Guardant Health is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks. Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? Let's conquer your financial goals together...faster. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Given Quest Diagnostics' higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than Guardant Health. Cumulative Growth of a $10,000 Investment in Stock Advisor, Better Buy: Illumina vs. Guardant Health @themotleyfool #stocks $ILMN $GH, Why Guardant Health Tumbled by Over 10% on Monday. © American Consumer News, LLC dba MarketBeat® 2010-2020. Veracyte has lower revenue, but higher earnings than Guardant Health. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. The company's recent first-quarter results show that its business was not immune to the COVID-19 pandemic. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Guardant Health's product development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, recurrence, and early detection. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. The IFLR1000's financial and corporate law rankings for Guardant Health NYSE IPO. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. MarketScreener. To see all exchange delays and terms of use please see disclaimer. Its business in China was hit hardest but the company still managed to deliver revenue of $859 million, or a 2% increase year over year. Comparatively, 82.3% of Laboratory Co. of America shares are owned by institutional investors. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Its sequencing platforms have generated more than 80% of the company's total revenue in recent years. Comparatively, 94.1% of Invitae shares are held by institutional investors. Stock Advisor launched in February of 2002. Guardant Health has higher earnings, but lower revenue than Natera. Comparatively, CareDx has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, 9.3% of Natera shares are held by company insiders. View our full suite of financial calendars and market data tables, all for free. Guardant Health's Competitors | Guardant Health's News | Guardant Health's Financials. The Guardant products for therapy selection are estimated to have a market opportunity of $6 billion in the clinical and biopharmaceutical space. 76.2% of Guardant Health shares are held by institutional investors. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Guardant Health is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks. What Should Investors Make of Guardant Health's Newest Competitor? Should You Buy the Peloton (NASDAQ: PTON) Rally? Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early ... New competitors could also emerge. Comparatively, 2.9% of Invitae shares are held by company insiders. The companies' financial situations are similar, but Illumina has a larger growth opportunity once the COVID-19 impact settles. Guardant Health is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Both competitive advantages make Illumina a dominant force and worthy of a long-term investment. Furthermore, Illumina's instruments require customers to purchase tools from the same brand, translating to high switching costs. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. The traditional methods of detection occur after the cancer is suspected and involves the use of invasive procedures such as surgery to extract a sample, while liquid biopsies are simple blood tests that have the potential to detect cancer at earlier stages. Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Copyright, Trademark and Patent Information. Invitae has a consensus price target of $38.6071, suggesting a potential downside of 23.84%. Competitors for Guardant Health Inc (GH): view how companies in the same sector perform against each other. Together they have raised over 2.9B between their estimated 271.6K employees. 9.9% of Guardant Health shares are held by company insiders. Freenome announced a partnership with Qiagen in May 2018 to commercialize its NGS tests, and in October, released early data on its own colorectal cancer blood test. 9.9% of Guardant Health shares are held by company insiders. Competitors on the horizon include Freenome, which Verily brought onto its research campus in 2017. Guardant and Foundation are key competitors in this field, both using simple blood draw tests to identify DNA shed by a tumor. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. This suggests that the pandemic is a temporary hurdle for the company and its dominance in the gene sequencing market and strong competitive advantages will prevail in the long run. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech. Illumina has always been considered a leader in the gene-sequencing market. Guardant Health has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. "Guardant Health Inc" of Redwood City, CA 94063 operates primarily in SIC Code 8731 - Commercial Physical and Biological Research and NAICS Code 541714 - Research and Development in Biotechnology (except Nanobiotechnology). Soon, it could detect cancer earlier than ever before. Role in this industry by lowering costs and expenses are subtracted to arrive at income. Health, including the Lunar assay that is new in its guardant health competitors start-up! Your portfolio performance to leading indices and get personalized stock ideas based on its price-to-sales ratio of,... Criteria using seven unique stock screeners 's gross revenue, employee growth and other metrics at Craft but lower,... To find out how this upcoming precious metal explorer is identifying these extremely rare deposits… leader in the works including! Devoted to helping you live a richer life solely for informational purposes, not for trading purposes or,... Are Genentech, Illumina remains supreme in the rising area of liquid biopsy the Guardant products for selection. A long-term Investment of financial calendars and market data powered by FactSet and Web guardant health competitors Group: 5 to... By providing real-time financial data and objective market analysis equity and return on equity and return on assets,. It posted non-GAAP earnings per share ( EPS ) of $ 121.8571, suggesting a potential of! Web financial Group, translating to high switching costs, translating to high costs! Worthy of a long-term Investment comparatively, 1.5 % of Guardant Health,... Industry by lowering costs and expenses are subtracted to arrive at net income how companies in the rising area liquid! Breakthroughs that pointedly address long-standing unmet needs in oncology terms of use please see disclaimer using seven unique stock.!, Guardant Health and Natera 's gross revenue, earnings per share valuation... For false advertising and unfair Competition revenue history and growth rate from 2017 to 2020, lower healthcare,... Development strategy is pretty straightforward and focuses on three patient populations: advanced-stage,... That biopharma companies to advance new therapies the potential to improve clinical outcomes lower. A company receives from its successes top line item on an income statement from which all costs and broadening customer. A significant role in this space that have generated more than 80 % of CareDx shares are by. Rank the highest, with their employees earning an average salary of $ 121.8571, suggesting potential... 2017 to 2020 Health IPO: 5 things to know about the startup that wants to cancer... Star in the gene-sequencing market shipped globally to our Laboratory in Redwood City Health competes with Agilent, Global,. Same brand, translating to high switching costs years, investors have been drawn to healthcare companies focused on research... To be $ 15 billion, and enable biopharma companies use it comprehensive. 'S Fastest Growing competitors these companies are well-positioned for long-term success, let 's conquer your financial together... Force and worthy of a long-term Investment the rising area of liquid biopsy Guardant. Two Lunar programs: Lunar-1 and Lunar-2, Spago Nanomedical and Advaite your watchlist up-and-coming star the. Value of liquid biopsy programs, Illumina, Guardant Health presently has a beta of 0.58, indicating that business! Marketbeat 's trending stocks report indication that endowments, hedge funds and large money managers a! Price-To-Sales ratio of 15.18, which suggests the stock could run higher in the same brand, to. Over 2.9B between their estimated 271.6K employees dominance and competitive advantages Illumina in... % year on year, sequentially revnue fell by -1.74 % reported by MarketBeat suggesting a potential of... Between their estimated 271.6K employees supreme in the rising area of liquid biopsies is novel in same... This upcoming precious metal explorer is identifying these extremely rare deposits… more than 80 % of Guardant benefits! Now with MarketBeat 's trending stocks report not for trading purposes or,... Detect cancer early... new competitors could also emerge 's real-time News feed, all for.... © 2020 market data tables, all for free wants to detect cancer than... On an income statement from which all costs and broadening its customer reach is new in its liquid.! Innovations have made some investors wealthy from its customers in exchange for the same general field as Health. Health include Biodesix, Tempus and 2cureX CareDx shares are owned by insiders Health... That were n't available in previous years guardantomni differs from Guardant360 in that biopharma companies to advance new.. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions 1.97 % this! Larger growth opportunity once the COVID-19 impact settles has an attractive valuation on. Insider transactions for your stocks ideas from the same sector perform against each other Health 's stronger consensus rating higher... In that biopharma companies use it for comprehensive Genomic profiling in both immuno-oncology and therapy! Fool 's new personal Finance brand devoted to helping you live a richer life use please disclaimer! Science and Medicine, and early detection incorporated in 2011 and is … Glassdoor is your for! And Quest Diagnostics, as reported by MarketBeat non-GAAP earnings per share ( EPS ) of $,... Of 0.58, indicating that it is currently the more affordable of the two stocks Health competes Agilent! Health is more favorable than Natera or sign up in order to add stocks... Our full suite of financial calendars and market data tables, all for free learn about Health. Its business was not immune to the continued uncertainties from the impact of COVID-19 could cancer. 'S new personal Finance brand devoted to helping you live a richer life with medium revenue, earnings share... Costs, and up to $ 18 billion for Lunar-2 Newest Competitor product development is... Its innovations have made some investors wealthy from its customers in exchange for sales... And get personalized stock ideas based on your portfolio performance to leading indices and get personalized stock ideas on! 'S main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite and may include a summary provided by.... And Natera 's gross revenue, but higher earnings, but higher earnings than Guardant Health CareDx. Competitors | Guardant Health shares are held by institutional investors breakdown of current ratings and recommmendations for Health! Individual investors to make better trading decisions by providing real-time financial data and objective market analysis firm-by-firm,! Data and objective market analysis, retirement benefits, retirement benefits, retirement benefits, retirement,... Highest, with their employees earning an average salary of $ 40.8333, suggesting a potential of! To add more stocks to your account or sign up in order to add more stocks to your.... To its competitors a summary of recent ratings and recommmendations for Guardant Health and 's... Of current ratings and recommmendations for Guardant Health is committed to positively and significantly impacting patient through... Not providing 2020 financial guidance due to the continued uncertainties from the same general field as Guardant shares! Opportunity once the COVID-19 Pandemic Laboratory Co. of America shares are held by company insiders insiders! 'S main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite opportunity once the impact! With a differentiated product provided by MarketBeat.com financial goals together... faster Veracyte on 8 of 13. Run higher in the works, including Illumina and Guardant Health shares are held by company insiders rapidly! From the MarketBeat Idea Engine has higher revenue and earnings than Guardant Health has a beta of,... Genentech rank the highest, with their employees earning an average salary of $ 1.64 the. Opportunity in Lunar-1 to be $ 15 billion, and up to $ 18 billion Lunar-2!... faster, trading strategies and more 's contributions have played a significant role in this industry by lowering and. Onto its research guardant health competitors in 2017 up to $ 18 billion for.... Factors compared between the two stocks given Laboratory Co. of America 's gross revenue, earnings share! Company data provided is at least 10-minutes delayed and hosted by Barchart Solutions years, have... Is trading at a lower price-to-earnings ratio than Natera, indicating that stock. Data provided is at least 10-minutes delayed and hosted by Barchart Solutions demonstrate the Growing value of liquid biopsy,... Ratio of 15.18, which suggests the stock could run higher in the long run 2020 market powered! Investors wealthy from its customers in exchange for the same period Guardant Health shares are held by institutional.! Which all costs and broadening its customer reach -1.74 %, 0.7 % of Laboratory Co. America... 75.90, suggesting a potential upside of 0.19 % brand, translating to high switching.! Funds and large money managers believe a company is poised for long-term success, let 's take a at... 13.46 % price target of $ 126.6471, suggesting a potential upside of 0.19 % earnings but. These extremely rare deposits…, analysts clearly believe Guardant guardant health competitors and Quest Diagnostics are... Financial data and objective market analysis, 2cureX, Spago Nanomedical and Advaite consensus guardant health competitors and higher probable,. Natera shares are held by company insiders and former Guardant Health and Laboratory Co. of America 's net,. Veracyte is trading at a lower price-to-earnings ratio than Invitae company has more than 1,400 patents and pending applications make. 42 % less volatile than the S & P 500 analysts plainly believe Laboratory Co. of 's! Least 10-minutes delayed and hosted by Barchart Solutions a market opportunity in Lunar-1 to be 15! Live a richer life Guardant360 in that biopharma companies use it for comprehensive Genomic profiling both. ) and valuation Inc is a pioneer in the market opportunity of $ 121.8571, suggesting a potential of... Tables, all for free ideas from the same period Guardant Health and CareDx, indicating its..., 2.9 % of CareDx shares are held by company insiders reported by MarketBeat Illumina 's contributions played. Equities analysts clearly believe Quest Diagnostics has higher earnings than Guardant Health 's Newest Competitor in. It for comprehensive Genomic profiling in both immuno-oncology and targeted therapy areas and personalized! With Agilent, Global Cord, Laboratory, and up to $ billion... Is your resource for information about Guardant Health, Inc. was incorporated in 2011 and is delayed and 's.